Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 10;6(9):2920-2926.
doi: 10.1182/bloodadvances.2021005953.

Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL

Michael Northend  1   2 , William Wilson  2 , Wendy Osborne  3 , Christopher P Fox  4 , Andrew J Davies  5 , Dima El-Sharkawi  6 , Elizabeth H Phillips  7   8 , Hau Wui Sim  9 , Shalal Sadullah  10 , Nimish Shah  11 , Ying Ying Peng  12 , Iman Qureshi  13 , Juanah Addada  14 , Rocio Figueroa Mora  4 , Neil Phillips  15 , Andrea Kuhnl  16 , Elizabeth Davies  17 , David Wrench  18 , Pamela McKay  19 , Indrani Karpha  20 , Anna Cowley  21 , Richard Karim  22 , Sarah Challenor  23 , Vikram Singh  24 , Cathy Burton  25 , Rebecca Auer  26 , Chris Williams  27 , Joel Cunningham  10 , Angus Broom  28 , Anita Arasaretnam  29 , Claire Roddie  1 , Tobias Menne  3 , William Townsend  1
Affiliations

Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL

Michael Northend et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Treatment subgroups according to treatment intent, treatment response rates, PFS and OS. (A) Pola-BR treatment subgroups according to treatment intent. (B) Response rates to Pola-BR. (C) PFS and OS. (i) PFS and (ii) OS for all patients. (iii) PFS for patients in the stand-alone Pola-BR cohort (no planned SCT or CAR T-cell therapy) according to treatment response. CI, confidence interval; HR, hazard ratio; PR, partial response. (iv) OS for patients in the stand-alone Pola-BR cohort (no planned SCT or CAR T-cell therapy) according to treatment response.
Figure 1.
Figure 1.
Treatment subgroups according to treatment intent, treatment response rates, PFS and OS. (A) Pola-BR treatment subgroups according to treatment intent. (B) Response rates to Pola-BR. (C) PFS and OS. (i) PFS and (ii) OS for all patients. (iii) PFS for patients in the stand-alone Pola-BR cohort (no planned SCT or CAR T-cell therapy) according to treatment response. CI, confidence interval; HR, hazard ratio; PR, partial response. (iv) OS for patients in the stand-alone Pola-BR cohort (no planned SCT or CAR T-cell therapy) according to treatment response.
See this image and copyright information in PMC

References

    1. Chaganti S, Illidge T, Barrington S, et al. ; British Committee for Standards in Haematology . Guidelines for the management of diffuse large B-cell lymphoma. Br J Haematol. 2016;174(1):43-56. - PubMed
    1. Philip T, Guglielmi C, Hagenbeek A, et al. . Autologus bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333(23):1540-1545. - PubMed
    1. Schuster SJ, Bishop MR, Tam CS, et al. ; JULIET Investigators . Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45-56. - PubMed
    1. Locke FL, Ghobadi A, Jacobson CA, et al. . Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20(1):31-42. - PMC - PubMed
    1. Kuhnl A, Roddie C, Martinez-Cibrian N, et al. . Real-world data of high-grade lymphoma patients treated with CD19 CAR-T in England [abstract]. Blood. 2019;134(supplement_1). Abstract 767.

MeSH terms